Robert Gunnarsson has been the CEO of Navinci since 2020. Mr Gunnarsson holds nearly 20 years of experience from Life Science and Biotech industry.He joined most recently from the ImmunoDiagnostic Division of Thermo Fisher Scientific where he was Director of Project & Portfolio Management. He has previously held positions as Managing Director of R&D, R&D Manager and Development Scientist in Mercodia AB and Gyros AB, from where he gained expertise in immunoassay development and strategic business development. He has a proven track record in successful development and commercialization of research and In Vitro Diagnostic products. He studied biotechnology at Uppsala University and later an Executive MBA from Mgruppen, Stockholm.
Agata has been the Chief Product & Science Officer of Navinci since 2020. She brings 15 years of experience developing innovative solutions and methodologies in molecular medicine. She joined the company in 2016 as a Head of Laboratory and Biomarker Assays. Since then, she has been leading the development of the NaveniFlex product family, providing scientific leadership to the Navinci team and expert opinions to customers and collaborators. Agata has extensive experience in immunoassay technology design and development and a deep understanding of cell and molecular biology methods, histology, and imaging techniques. She has earned an MSc in Molecular Biotechnology and a Ph.D. in Molecular Medicine from the Uppsala University in Sweden and continued her academic career as a researcher at the Human Protein Atlas and SciLife Laboratory. During that time, she developed new technologies for patient sample analysis, established innovative protein-DNA conjugation methods, and applied in situ assays for novel biomarker exploration.
Subham Basu has hands-on expertise across all facets of life sciences and biopharma, from pre-clinical research to marketing. He comes to us from Abcam, where he was the Senior Director for Commercial Strategy for Immuno-oncology and Oncology. He has served as an advisor to the pharmaceutical and diagnostic industries as well as to venture capital funds as Head of Strategy at Inflection Point Biomedical Advisors. He has extensive experience in biotech/pharma in medical affairs and market access at AZ, Shire/Baxalta, Otsuka Pharmaceuticals and Genzyme, working in oncology, hematology and rare diseases. Prior to these wide-ranging industry roles, Subham directed a competitive cancer research laboratory funded by CRUK, focused on signalling and cell biology at Barts Cancer Institute in London. He has a PhD in Molecular Pharmacology from Cornell’s Weill Graduate School of Medical Sciences (labwork at Memorial Sloan Kettering Cancer Center) and BS in Neuroscience from University of California at Berkeley.
Caroline joined Navinci as CTO in November 2022 and brings extensive experience in the fields of spatial genomics and proteomics. Caroline previously held the role of R&D Director, 10x Genomics Stockholm where she was responsible for spatial technology development and site management. Prior to 10x Genomics, Caroline was a fellow with Ulf Landegren, Molecular Tools Program and then group leader at Uppsala University where her laboratory developed new approaches for single cell analysis and affinity-based protein detection. Caroline is a graduate of McGill University, Canada where she received her Ph.D. in Human Genetics.
Eva Pisa is a leader in health diagnostics and biotechnology and has extensive leadership experience from start-up to corporate companies. She earned her PhD in immunology at the Karolinska Institute in Stockholm Sweden, and she holds an MBA from Heriot-Watt University, Edinburgh, Scotland.
Eva Pisa was the CEO of a Swedish molecular diagnostic start-up from 2001 and 2007 that was acquired by Cepheid now a part of Danaher. The company was specialized in infectious disease affecting immune compromised patients. Eva Pisa subsequently joined Roche Diagnostics International where she held responsibilities including Life Cycle Leader Microbiology and Global Head of Product Development for Roche Molecular Diagnostics (2007-2016). During her tenure the highly successful Roche cobas 6800 and 8800 System was developed and launched. As an SVP at Roche Centralized and PoC Solutions (2016-2020) she was responsible for the Clinical Chemistry, Endocrinology and Custom Biotech (B2B business) and retired from Roche Diagnostics International in 2020.
Eva Pisa continues to support and consult with diagnostic and life science companies through piMed Consulting AG, and she is a board member of HSE AG, Hombrechtikon, Switzerland, Envetec, Ballina, Ireland and Qiagen NV, Venlo, Holland.
Professor Landegren has been a pioneer of molecular detection technologies and world leading scientist in molecular biology for more than 40 years. He and his colleagues developed the in situ proximity ligation technique and a long line of innovations based on the principle of dual recognition and oligonucleotide hybridization, resulting in widely used applications for both nucleic acid and protein detection. He is the author of more than 220 publications and co-inventor of more than 45 patents.
Professor Landegren is the cofounder of several companies, including Olink AB/Navinci Diagnostics AB, Olink Proteomics AB, HaloGenomics AB, and Q-Linea AB. He is a member of the Swedish Royal Academy of Sciences and the European Molecular Biology Organization, and he has been or is currently member of scientific advisory boards for more than 10 companies.
Maria Tell has over 15 years of experience in marketing, strategy, business development, investment, and investor relations within the Life Science and MedTech industry, in senior roles. She acts as Investment Director for Segulah Medical Acceleration (SMA) and holds a Master of Science in Molecular Biology from Uppsala University and a degree in Marketing and Business Administration from the School of Entrepreneurship, Uppsala University. Prior to joining SMA she held roles at GE Healthcare, Accelerator Nordic AB, SyntheticMR AB, and Almi Invest. Maria has vast experience from board roles including Cartana and Single Technologies, and currently serves on the board of directors for CytaCoat.
Jon-Sverre brings a vast experience and expertise from more than 35 years in the life science industry. He has a PhD Biochemistry at the University of Bergen, Norway, studying biological effect of anti-metabolites targeting cancer, and has held variuos executive positions, including Chief Scientific Officer at Biotage AB, Vice President of R&D of ImmunoDiagnostic Division at Thermo Fisher Scientific, Chief Technology Officer for Gyros Microsystems AB, and Vice President of R&D in Dako A/S Denmark (now Agilent). Jon-Sverre started his industrial career as a researcher in drug discovery at Nycomed ASA focusing on immunomodulating peptides.
Jonas holds a Master of Laws (jur. kand.) degree from Uppsala University, including studies at Vrije Universiteit Amsterdam and University of California, Berkeley, and an advanced Master of Laws (LL.M.) degree in European Intellectual Property Law from Stockholm University. He has 15+ years of experience from the life science industry from roles as corporate lawyer at Elekta and Galderma (Q-Med), as associate at law firm Lindahl and as owner of and principal consultant at Biolegal where he specializes in assisting life science companies with business and operations related legal matters.
Professor Kämpe has extensive experience as a medical doctor and researcher in molecular biology, immunology and clinical medicine, with more than 170 publications in scientific journals. He is Professor in endocrinology at Karolinska Institute with previous roles are as Professor in molecular medicine at Uppsala University for 15 years. For his research, he was honored with the Jubilee Prize and Centenary Medal by the Swedish Medical Society in 2016, and was awarded the European Hormone Medal by European Society of Endocrinology in 2020. He is a member of the Royal Swedish Academy of Science (class for medical sciences) since 2011. Professor Kämpe has been director of the board of Olink AB/Navinci Diagnostics AB since 2011. Among other assignments, he serves on the scientific advisory board of Segulah Medical Acceleration.
Ulf Landegren received his MD and PhD in Uppsala, Sweden, before spending five years at the California Institute of Technology. As a professor of molecular medicine in Uppsala his research focuses on developing molecular tools to meet needs in basic research and medicine, from analyses of genetic variation with techniques such as oligonucleotide ligation assays and padlock probes to protein assays using oligonucleotide-conjugated antibodies in proximity assays for measuring protein expression levels in liquid samples or imaging their distribution in situ.
Professor Landegren is a member of EMBO, the Royal Swedish Academy of Sciences, and the Royal Society of Sciences at Uppsala. He is a member of several academic or industrial boards and advisory boards. He has authored 230 peer-reviewed publications and is the inventor of some 50 patents or applications. Work in his lab has so far given rise to 12 spin-out companies with a combined staff of more than 900 people, including two publicly traded companies (Olink Proteomics and Q-linea). Technologies from his lab have also been licensed to many leading international biotech and diagnostic companies.
Carolina Wählby is professor in Quantitative Microscopy at the Dept. of Information Technology, Uppsala University, Sweden, and Scientific Director of the Swedish National SciLifeLab Bioimage Informatics Unit. Her research is focused on developing computational approaches for extracting information from image data with applications in life science; primarily at the microscopy scale. Methods include traditional image analysis and computer vision technology as well as AI and deep learning. The goal of the analysis ranges from predicting and understanding dynamics of cancer cells to fast antibiotics susceptibility testing and ‘functional pathology’ combining tissue morphology with spatial transcriptomics. The research is primarily funded by the ERC and the Swedish Foundation for Strategic research. She received the SBI2 President’s innovation award in 2014 for her pioneering work on in situ sequencing, and the Thuréus prize in 2015 for development of open tools for image analysis. She is a member of the Royal Society of Sciences at Uppsala and the Royal Swedish Academy of Engineering Sciences. She has a MSc in molecular biotechnology and a PhD in digital image analysis, and carried out postdoc research within genetics and pathology. She worked at the Imaging Platform of the Broad Institute of Harvard and MIT in 2009-2015 and became full professor at Uppsala University in 2014. She is a member of the steering group of a 300M€ effort on Data Driven Life Science, funded by the Knut and Alice Wallenberg Foundation, with the ambitious goal of training the next generation of life scientists. Her heart lies in the intersection between life science and computational image analysis, and she is intrigued by the possibilities of novel technological developments and convergence of the scientific fields.
Jan Andersson has been a professor of medicine at the Karolinska Institutet with focus on infectious diseases since 1998 at Department of Medicine. He was 2010-2013 Deputy President of the Karolinska Institutet and 2013-2020 Research Director of The Region Stockholm. During 2004-2019 he served as a member of the Nobel Committee for Physiology or Medicine. He was awarded the Feinstein Institute, New York award for science and education in 2007, The Royal Institute of Technology:s Gold Medal award for Innovation and Development in 2021 and the Karolinska Institutet:s Large Silver medal for contribution in science in 2022. Jan Andersson holds a position as chairman for the scientific advisory board for Segulah Medical Acceleration and Editor for Journal of Internal Medicine.
Dr. Daniel Fürth is a molecular tool developer and neuroscientist whose research focuses on understanding how information is stored, processed, and transmitted between cells. He completed his Ph.D. in neuroscience at Karolinska Institutet, where he used modified rabies virus tracing to investigate mesoscale connectomics. After his Ph.D., he pursued postdoctoral work at the Cancer Center of Cold Spring Harbor Laboratory in New York, where he focused on developing methods for enabling functional RNA genomics in situ at subcellular single-molecule resolution.
As an assistant professor and SciLifeLab fellow at Uppsala University, Dr. Fürth leads a team of molecular biologists and synthetic chemists who develop novel molecular tools to read and write information at the single-molecule level, which they leverage to answer long-standing questions in neuroscience. They combine nonlinear optical microscopy with chemoselective moieties to develop new ways of perturbing and interrogating information at the single-molecule level. One of the main goals of their research is to identify unknown mechanisms that can transfer symbolic information between cells, which could have significant implications for our ability to read and write such messages in the future.
Dr. Mats Nilsson (MN) is a professor of Biochemistry at Stockholm University and Director of the Spatial and Single Cell Biology Platform at SciLifeLab in Stockholm and Uppsala. Nilsson leads a group at SciLifeLab dedicated to developing and applying spatial omics methods to resolve molecular and cellular diversity in human and mouse tissue sections from organs and whole embryos. The core activity is the development of protocols and reagents (wetware), but also to co-develop computational tools (software) and imaging systems (hardware) with collaborators to establish complete analysis systems. He is engaged in several Human Cell Atlas projects, with particular emphasis on human development. He has a long-standing interest in trying to deconvolute intra-tumoral heterogeneity through in situ genotyping and phenotyping. Nilsson has pioneered padlock probe and RCA technologies which has generated 6 spin-out companies and further adoption by numerous companies. content Goes Here.
Martin Stern received his MD from the Basel University in Switzerland, where he underwent post-graduate training in internal medicine, oncology and hematology. Specializing in hematopoietic stem cell transplantation, he became interested in cancer and transplant immunology and in 2010 founded the Cancer Immunotherapy Lab at the Department of Biomedicine which he led for several years as a Swiss National Science Foundation research professor while still working part time at Basel University Hospital. He authored over 100 peer-reviewed publications during this time and initiated trials of adoptive cell therapy for patients with hematological malignancies.
In 2014, he left academic research and clinical medicine to join Roche Pharma Research and Early Development to work the next several years in bringing early cancer immunotherapy molecules to clinical proof of concept. During the next 8 years, he was involved in early clinical development and translational aspects of antibody based candidate molecules covering the entire spectrum of oncoimmunology approaches. In 2022, Martin joined the biotechnology startup company Affivant as Chief Medical Officer, where he is overseeing the clinical development group.